Serum C-reactive protein: A useful and economical marker of immune activation in renal transplantation

Transplantation

Volumn 61, Issue 11, 1996, Pages 1593-1600

  Harris, Katie R ^a   Digard, Nicholas J ^a   Lee, Harry A ^a  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; MIZORIBINE; OKT 3; THYMOCYTE ANTIBODY;

ACUTE KIDNEY TUBULE NECROSIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; C-REACTIVE PROTEIN; CREATININE; CYCLOSPORINE; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; METHYLPREDNISOLONE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; URINARY TRACT INFECTIONS;

EID: 0029982581     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199606150-00008     Document Type: Article

References (72)

1. Sibley RK. Pathology and immunopathology of solid organ graft rejection. Transplant Proc 1989; 21: 14.
2. Tilney NL, Kupiec-Weglinski JW. Advances in the understanding of rejection mechanisms. Transplant Proc 1989; 21: 10.
3. Colvin RC. Cellular and molecular mechanisms of allograft rejection. Annu Rev Med 1990; 41: 361.
4. Hall BH. Cells mediating allograft rejection. Transplantation 1991; 51: 1141.
5. Kirk AD, Ibrahim MA, Bollinger RR, Dawson DV, Finn OJ. Renal allograft infiltrating lymphocytes. Transplantation 1992; 53: 329.
6. Henney C. The interleukins as lymphocyte growth factors. Transplant Proc 1989; 21: 22.
7. Halloran PF, Cockfield S, Madrenas J. The mediators of inflammation (interleukin-1, interferon gamma, and tumour necrosis factor) and their relevance to rejection. Transplant Proc 1989; 21: 26.
8. Van Krams SM, Falco DA, Villaneuva JC, et al. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation 1992; 53: 151.
9. Wu CJ, Lovett M, Wong-Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation 1992; 54: 326.
10. Maessen JG, Buurman WA, Koostra G. Direct cytotoxic effect of cytokines in kidney parenchyma: a possible mechanism of allograft destruction. Transplant Proc 1989; 21: 309.
11. Solez K, McGraw DJ, Beschorner WE, et al. Reflections on use of the renal biopsy as the "gold standard" in distinguishing transplant rejection from cyclosporin nephrotoxicity. Transplant Proc 1985; 17: 123.
12. Dallman MJ, Wood J, Morris PJ. Specific cytotoxic T cells are found in the non-rejected kidneys of blood-transfused rats. J Exp Med 1987; 2: 566.
13. Wood KJ, Dallman MJ, Morris P. Cytotoxic cells alone are not sufficient to mediate renal graft rejection. Transplant Proc 1989; 21: 338.
14. Seron D, Diaz-Gallo C, Grino JM, et al. Characterisation of interstitial infiltrate in early renal allograft biopsies in patients with stable renal function. Transplant Proc 1991; 23: 1267.
15. Farges O, Kalil AN, Sebagh M, Reynes M, Bismuth H. Low incidence of chronic rejection in patients experiencing histological acute rejection without simultaneous impairment in liver function test. Transplant Proc 1995; 27: 1143
16. Lipman M, Stevens AC, Bleackley RC, et al. The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation 1992; 53: 73.
17. Martinez O, Krams SM, Sterneck M, et al. Intragraft cytokine profile during human liver allograft rejection. Transplantation 1992; 53: 449.
18. Caillat-Zuckerman S, Vanden Broecke C, Legendre C, et al. Differential in situ expression of cytokine genes in human renal rejection. Transplant Proc 1991; 23: 229.
19. Dallman M, Roake J, Hughes D, Toogood G, Morris J. Sequential analysis of IL-2 gene transcription in renal transplants. Transplantation 1992; 53: 683.
20. Norohna IL, Weis H, Hartley B, Wallach D, Cameron JS, Waldherr R. Expression of cytokines, growth factors and their receptors in renal allograft biopsies. Transplant Proc 1995; 27: 917.
21. Ford HR, Hoffman RA, Wang SA, Simmons RL. Profile of cytokine production within the rejecting allograft. Transplant Proc 1991; 23: 251.
22. Maury CPJ, Teppo AM. Serum immunoreactive interleukin-1 in renal transplant recipients. Association of raised levels with graft rejection episodes. Transplantation 1988; 45: 143.
23. Albert FW, Schmidt U, Seyfert UT, Wurmell W, Gumbel W. Interleukin-2 measurements in peripheral blood after kidney transplantation. Transplant Proc 1990; 22: 1852.
24. Senitzer D, Greenstein SM, Louis P, et al. Monitoring serum IL-2r levels in cadaver renal transplantation: a prospective blinded study. Transplant Proc 1991; 23: 1279.
25. Schroeder TJ, Helling T, McKenna R, et al. A multicentre study to evaluate a novel assay for quantitation of soluble interleukin-2 receptor in renal transplant recipients. Transplantation 1992; 53: 34.
26. Jeyarajah D, Kadakia R, O'Toole K, et al. Changes in urinary cytokine mRNA profile after successful therapy for acute cellular renal allograft rejection. Transplant Proc 1995; 27: 887.
27. Daniel V, Pasker S, Wiesel M, et al. Cytokine monitoring of infection and rejection in renal transplant recipients. Transplant Proc 1995; 27: 884.
28. Robinet E, Ibrahim A, Truneh A, et al. Serum levels and receptor expression of tumor necrosis factor alpha following human allogenic and autologous bone marrow transplantation. Transplantation 1992; 53: 574.
29. Steiner G, Zlabinger G, Karamehic J, Pohanka E, Kovarik J, Woloszczuk W. Interferon-gamma, neopterin and interleukin-2 receptor levels in the serum of kidney transplant recipients. Transplant Proc 1990; 22: 1857.
30. Tono T, Monden M, Yoshizaki K, et al. Interleukin-6 levels in bile following liver transplantation. Transplant Proc 1991; 23: 630.
31. Simpson MA, Madras PN, Cornaby AJ, et al. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 1989; 47: 218.
32. Mclaughlin PJ, Aikiwa AA, Davies HM, et al. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 1991; 51: 1225.
33. Taupin JL, Morel D, Moreau JF, Gualde N, Potaux L. HILDA/ LIF urinary excretion during acute kidney rejection. Transplantation 1992; 53: 655.
34. Rondeau E, Cerrina J, Delarue F, et al. Tumour necrosis factor alpha production by cells of bronchoalveolar lavage and peripheral blood mononuclear cells in cardiopulmonary transplant recipients. Transplant Proc 1990; 22: 1855.
35. Vogel W, Tilg H, Herold M, et al. Cytokine production after liver transplantation. Transplant Proc 1990; 22: 1854.
36. Adams DH, Garner C, Neuberger JM. Serum tumour necrosis factor alpha in patients following liver transplantation. Transplant Proc 1990; 22: 2310.
37. Dittmer R, Harfmann P, Tenschert W, Arndt R, Busch B. Monitoring of renal transplant patients with interleukin-2 and interleukin-2 receptor enzyme immunoassay and interleukin-2 receptor immunocytology. Transplant Proc 1990; 22: 2284.
38. Kushner I, Broder ML, Karf D. Control of the acute phase response. J Clin Invest 1978; 61: 235.
39. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141.
40. Gewurz H, Mold C, Siegel J, Fiedel B. C-reactive protein and the acute phase response. Adv Intern Med 1982; 27: 345.
41. Ramadori G, Sipe JD, Dinarello CA, Mizel B, Colten HR. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin-1 (IL-1) and purified human IL-1. J Exp Med 1985; 162: 930.
42. Nijsten M, De Groot ER, Ten Duis HJ, Klasen HJ, Hack CE, Aarden LA. Serum levels of IL-6 and acute phase responses. Lancet 1987; 11: 921.
43. Gauldie J, Richards C, Harnish D, Lansdorf P, Baumann H. Interferon beta2/B cell stimulatory factor type 2 shares identity with monocyte derived hepatocyte stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251.
44. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237.
45. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253.
46. White J, Meyer E, Hardy MA. Prediction of the onset and termination of renal allograft rejection by serum levels of C-reactive protein. Transplant Proc 1981; 13: 682.
47. Freed B, Walsh A, Pietrocola D, MacDowell R, Laffin R, Lempert N. Early detection of renal allograft rejection by serial monitoring of serum C-reactive protein. Transplantation 1984; 37: 215.
48. Maury CPJ, Teppo AM. Comparative study of serum amyloid A related protein (SAA), C-reactive protein, and beta2 microglobulin as markers of renal allograft rejection. Clin Nephrol 1984; 22: 284.
49. Groth J, Kaden J, Hoffmann P, Muller K, Mrochen H, Mebel M. C-reactive protein and clinical kidney transplantation. Nephron 1984; 37: 236.
50. Lempert N, Freed B, Godlewski J, et al. C-reactive protein: an indicator of rejection episode severity in renal allograft recipients pretreated with donor-specific transfusions. Transplant Proc 1985; 17: 662.
51. Rowe IF, Magoha GA, El Malik F, Whitwan JG, Williams G, Pepys MB. Measurement of serum C-reactive protein concentration after renal transplantation. Nephrol Dial Transplant 1987; 2: 39.
52. Van Oers MHJ, Van Der Heyden AAPA, Aarden LA. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol 1988; 71: 314.
53. Yoshimura M, Oka T, Kahan BD. Sequential determination of serum interleukin-6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation 1991; 51: 172.
54. Lee HA, Slapak M, Venkatramen G, Mason JC, Digard N, Wise M. Mizoribine as an alternative to azathioprine in triple therapy immunosuppressant regimens in cadaveric renal transplantation: two successive studies. Transplant Proc 1995; 27: 1050.
55. Philip AGS, Andrews P. Rapid determination of C-reactive protein levels: semiquantitative versus quantitative. J Paediatr 1987; 110: 263.
56. Lalla MLT, Eklund B, Ahonen J. The clinical significance of C-reactive protein after renal transplantation. Transplant Proc 1988; 20: 402.
57. Hind CRK, Thompson SP, Winearls CG, Pepys MB. Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. J Clin Pathol 1985; 38: 459.
58. Mustard RA, Bohneon JMA, Haseeb S, Kasina R. C-reactive protein levels predict post-operative septic complications. Arch Surg 1987; 122: 69.
59. Schentag JJ, O'Keefe D, Marmion M, Wels P. C-reactive protein as an indicator of infection relapse in patients with abdominal sepsis. Arch Surg 1984; 119: 300.
60. Fisher CL, Gill C, Forrester MG, Nakamura R. Quantitation of "acute phase proteins" postoperatively. Am J Clin Pathol 1976; 66: 840.
61. Cohen DJ, Benvenisty AI, Meyer E, Hardy MA. Serum C-reactive protein concentrations in cyclosporine treated renal allograft recipients. Transplantation 1988; 45: 919.
62. Van Lente F, Castellani W, Abbott LB. Changes in concentrations of C-reactive protein in serum after kidney or heart transplantation. Clin Chem 1986; 32: 633.
63. Enwright H, Coyle M, O'Connell LG. C-reactive protein concentrations pre- and post-transfusion. Clin Lab Haematol 1990; 12: 25.
64. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann NY Acad Sci 1982; 389: 406.
65. Charpentier B, Lantz O, Lang PH, Martin B, Fies D. Release of interleukins during tolerance and rejection of human renal allografts. Transplant Proc 1987; 19: 1572.
66. Yoshimura N, Kahan BD, Oka T. The in vivo effect of cyclosporine on interleukin-6 gene expression in renal transplant recipients. Transplant Proc 1991; 23: 958.
67. Burdick JF, Kittur DS. Factors affecting early diagnosis of organ allograft rejection. Transplant Proc 1991; 23: 2047.
68. Kirby JA, Morgan JC, Shenton BK, Lennard TWJ, Proud G, Taylor RMR. Renal allograft rejection: functional impairment of kidney epithelial cell monolayers by lymphokine activated killer cells and by antibody. Transplantation 1991; 51: 891.
69. Ribeiro De Castro MC, Davi DSR, Azevado LS, Sabbaga E, Arap S. Should we treat a severe acute cellular rejection with no clinical signs? Transplantation 1991; 51: 1301.
70. Ruiz P, Coffman TM, Howell DN, et al. Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection. Transplantation 1988; 45: 1.
71. Von Willebrand E, Salmela K, Isoniemi H, Krogerus L, Taskinen E, Hayry P. Induction of HLA class II antigen and interleukin-2 receptor expression in acute vascular rejection of human kidney allografts. Transplantation 1992; 53: 1077.
72. Katz SM, Greenstein SM, Simonian S, et al. Inflammatory mediators in allograft malfunction: a new concept in the cyclosporin era. Transplant Proc 1989; 21: 304.